Evidence map›Paper›PMID 31911242›Full record

ArticleBiochimica et biophysica acta. General subjects2020

Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).

Alexander D MacKerell, Sunhwan Jo, Sirish Kaushik Lakkaraju, Christoffer Lind, Wenbo Yu

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. General subjects, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 62 citations in OpenAlex.

  1. Automated pharmacophore hypothesis generator for SILCS-Pharm: ph4gen.Journal of computer-aided molecular design · 2026
    Article
  2. Article
  3. Article
  4. The journal of physical chemistry. B · 2026
    Article
  5. Frontiers in bioinformatics · 2026
    Review
  6. Computational Ligand-Binding Site Prediction.Advances in experimental medicine and biology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander D MacKerellComputer Aided Drug Design Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, MD 21201, United States of America. Electronic address: alex@outerbanks.umaryland.edu.
Sunhwan JoSilcsBio, LLC, 8 Market Place, Suite 300, Baltimore, MD 21202, United States of America.
Sirish Kaushik LakkarajuSilcsBio, LLC, 8 Market Place, Suite 300, Baltimore, MD 21202, United States of America.
Christoffer LindComputer Aided Drug Design Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, MD 21201, United States of America.
Wenbo YuComputer Aided Drug Design Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, MD 21201, United States of America.
University of Maryland, Baltimore · USSilcsBio (United States) · US

Funding

Macromolecular Conformational HeterogeneityR35GM131710 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ALEXANDER D MACKERELL · 2019 to 2026
$6.2M
Pre-computed free energy maps for rapid structure-based ligand designR44GM109635 · NIGMS · SILCSBIO, LLC · PI LAKKARAJU, SIRISH KAUSHIK, MACKERELL, ALEXANDER D · 2016 to 2018
$1.3M
Pre-computed free energy maps for rapid structure-based ligand designR43GM109635 · NIGMS · SILCSBIO, LLC · PI MACKERELL, ALEXANDER D, MALONE, KENNETH GEORGE · 2015 to 2016
$234k
NIGMS NIH HHS R35 GM131710NIGMS NIH HHS R43 GM109635NIGMS NIH HHS R44 GM109635
6 · The paper itself

Abstract

backgroundFragment-based ligand design is used for the development of novel ligands that target macromolecules, most notably proteins. Central to its success is the identification of fragment binding sites that are spatially adjacent such that fragments occupying those sites may be linked to create drug-like ligands. Current experimental and computational approaches that address this problem typically identify only a limited number of sites as well as use a limited number of fragment types.

methodsThe site-identification by ligand competitive saturation (SILCS) approach is extended to the identification of fragment bindings sites, with the method termed SILCS-Hotspots. The approach involves precomputation of the SILCS FragMaps following which the identification of Hotspots, performed by identifying of all possible fragment binding sites on the full 3D structure of the protein followed by spatial clustering.

resultsThe SILCS-Hotspots approach identifies a large number of sites on the target protein, including many sites not accessible in experimental structures due to low binding affinities and binding sites on the protein interior. The identified sites are shown to recapitulate the location of known drug-like molecules in both allosteric and orthosteric binding sites on seven proteins including the androgen receptor, the CDK2 and Erk5 kinases, PTP1B phosphatase and three GPCRs; the β2-adrenergic, GPR40 fatty-acid binding and M2-muscarinic receptors. Analysis indicates the importance of considering all possible fragment binding sites, and not just those accessible to experimental methods, when identifying novel binding sites and performing ligand design versus just considering the most favorable sites. The approach is shown to identify a larger number of known binding sites of drug-like molecules versus the commonly used FTMap and Fpocket methods. GENERAL SIGNIFICANCE: The present results indicate the potential utility of the SILCS-Hotspots approach for fragment-based rational design of ligands, including allosteric modulators.

Indexed as

Molecular Docking SimulationAllosteric SiteBinding SitesCyclin-Dependent Kinase 5HumansLigandsMitogen-Activated Protein Kinase 7Protein Tyrosine PhosphatasesReceptor, Muscarinic M2Receptors, Adrenergic, beta-2Receptors, AndrogenReceptors, G-Protein-CoupledCyclin-Dependent Kinase 5FFAR1 protein, humanLigandsMAPK7 protein, humanMitogen-Activated Protein Kinase 7Protein Tyrosine PhosphatasesReceptor, Muscarinic M2Receptors, Adrenergic, beta-2Receptors, AndrogenReceptors, G-Protein-CoupledAllosteric pocketCompetitive inhibitorComputer-aided drug designCryptic pocketFragment-based drug designOrthosteric

Identifiers

PMID31911242
PMCPMC7029399
OpenAlexW2996822411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.